Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.
Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.
Bruker (Nasdaq: BRKR) reported Q1 2026 revenue of $823.4M, up 2.7% year-over-year and down 4.4% organically. Q1 GAAP diluted EPS was $0.02 and non-GAAP diluted EPS was $0.31. BSI bookings grew high-single-digits organically and book-to-bill stayed above 1.0x.
The company reconfirmed FY2026 guidance: revenue of $3.57–$3.60B (+4%–5% reported; +1%–2% organic) and non-GAAP EPS of $2.10–$2.15 (includes ~8% FX headwind).
Bruker (Nasdaq: BRKR) will report Q1 2026 financial results before market open on Wednesday, May 6, 2026, with a conference call and webcast at 8:00 a.m. ET.
A slide presentation will be posted shortly before the webcast. Investors may join via the investor website, phone (U.S. or international), or pre-register for a personalized dial‑in and PIN. A telephone replay is available through June 6, 2026.
Bruker (Nasdaq: BRKR) will showcase new cross-platform spatial biology workflows and high‑plex datasets at AACR 2026, including GeoMx-to-CellScape, CellScape-to-CosMx, a 208-plex CellScape XR spatial proteomics dataset, the PaintScape 419-plex panel, and commercial shipments expected this quarter or summer.
These updates emphasize integrated multiomic workflows linking whole transcriptome, proteomics, and 3D genome imaging for translational oncology research.
Bruker (NASDAQ:BRKR) announced portfolio enhancements at ESCMID Global 2026 across MALDI Biotyper, IR Biotyper, MBioSEQ Ridom Typer and integration of Molzym.
Key items: MBT Easy T kit (supports up to 2,000 samples), reference libraries expanded to 5,300+ species (+600 species), IVDR and US clinical studies targeting FDA submissions in 2026, and new IR Tracker outbreak surveillance capabilities.
Bruker (Nasdaq: BRKR) launched the MyGenius PRO high-throughput, fully automated sample-to-answer PCR molecular diagnostics system in Europe on April 17, 2026.
At launch the IVDR-compliant menu includes CMV, EBV (whole blood) and BKV (urine), with additional IVDR assays planned throughout 2026. The platform was co-developed with ELITechGroup and Hitachi High-Tech (Japan: LABOSPECT GA-5).
Bruker (Nasdaq: BRKR) unveiled new NMR hardware, software, and automated workflows at ENC 2026 to boost sensitivity, throughput, and reproducibility across research and applied NMR.
Key introductions include AVANCE NEO-X electronics, Advanced Chemical Profiling 2.0, the Fourier 80 Duo 80 MHz benchtop, new standard‑bore DNP probes, the Dynamis dissolution DNP system, NMRtist AI tools, RNA NMR toolkits, 160 kHz MAS solutions, Chemspeed automation, and SciY lab digitalization software.
Bruker (Nasdaq: BRKR) announced accelerated development of its photothermal AFM-IR spectroscopy and installation of a Dimension IconIR system at imec on April 7, 2026. The initiative expands AFM-IR use beyond contamination analysis into EUV photoresist, transistor scaling materials, and nanoscale surface functionalization.
The collaboration is a Joint Development Project with imec to evaluate nanoscale chemical characterization, citing label-free chemical analysis with sub-5-nanometer resolution to support advanced semiconductor research.
Bruker (Nasdaq: BRKR) appointed Thierry L. Bernard to its Board of Directors effective April 1, 2026. Mr. Bernard is an experienced life‑science tools and diagnostics executive and current CEO of QIAGEN, who has led molecular diagnostics since 2015 and became CEO in 2019.
The company said he will support Bruker’s strategy across life‑science research, biopharma and diagnostics as it pursues profitable growth and margin expansion.
PreOmics and Biognosys (BRKR) announced a favorable PTAB decision: the U.S. Patent Trial and Appeal Board revoked central claims of U.S. Patent No. 11,435,360 (IPR2024-01473), including the sole independent Claim 1.
The patent is owned by The Brigham and Women’s Hospital and exclusively licensed to Seer; the revoked claim covered workflows using multiple nanoparticle types to form biomolecule coronas to detect proteins.
Bruker (Nasdaq: BRKR) launched CellScape XR, a next-generation spatial proteomics platform designed for diagnostic and prognostic assay development. The platform emphasizes quantitative performance, robustness, and high throughput, incorporating advances in optics, fluidics, and protocols to support translational and clinical studies.
Bruker cites collaborations at University Hospital Schleswig-Holstein, Kiel, where teams analyzed >1,000 clinically annotated samples and plan to expand to ~3,000 patient samples, illustrating CellScape XR's intended scalability for large clinical cohorts.